Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$27.52−0.28 (-1.01%)
Close on Nov 17, 2026Market cap $3.07BP/E –Yield –
Amylyx Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Amylyx Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$126.58M. For fiscal 2025 it was -$123.34M. The highest annual figure on record is $11.92M in fiscal 2023.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$123.34M | – |
| FY2024 | Dec 31, 2024 | -$167.65M | -1506.6% |
| FY2023 | Dec 31, 2023 | $11.92M | – |
| FY2022 | Dec 31, 2022 | -$179.87M | – |
| FY2021 | Dec 31, 2021 | -$74.80M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$31.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$36.88M | – |
| Q4 FY2025 | Dec 31, 2025 | -$27.90M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.25M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -$59.01M | -535.5% |
| Q3 FY2024 | Sep 30, 2024 | -$41.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$66.58M | -873.4% |
| Q1 FY2024 | Mar 31, 2024 | -$489.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $13.55M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.17M | – |
| Q2 FY2023 | Jun 30, 2023 | $8.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.07M | – |
| Q4 FY2022 | Dec 31, 2022 | -$49.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$43.08M | – |
| Q2 FY2022 | Jun 30, 2022 | -$46.46M | – |
| Q1 FY2022 | Mar 31, 2022 | -$40.63M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.24M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.87M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.05M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.64M | – |
See a number that looks wrong?